Trevi Therapeutics [TRVI] vs Vertex [VRTX] Detailed Stock Comparison
Trevi Therapeutics
NASDAQ
Loading...
Vertex
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Trevi Therapeutics wins in 6 metrics, Vertex wins in 9 metrics, with 0 ties. Vertex appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Trevi Therapeutics | Vertex | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -17.55 | 28.08 | Trevi Therapeutics |
| Price-to-Book Ratio | 5.06 | 5.89 | Trevi Therapeutics |
| Debt-to-Equity Ratio | 0.45 | 8.89 | Trevi Therapeutics |
| PEG Ratio | 0.70 | -0.22 | Vertex |
| EV/EBITDA | -15.61 | 20.06 | Trevi Therapeutics |
| Profit Margin (TTM) | 0.00% | 31.86% | Vertex |
| Operating Margin (TTM) | 0.00% | 38.93% | Vertex |
| EBITDA Margin (TTM) | N/A | 38.93% | N/A |
| Return on Equity | -35.74% | 22.77% | Vertex |
| Return on Assets (TTM) | -22.83% | 13.09% | Vertex |
| Free Cash Flow (TTM) | $-38.29M | $-978.00M | Trevi Therapeutics |
| 1-Year Return | 144.81% | -18.72% | Trevi Therapeutics |
| Price-to-Sales Ratio (TTM) | N/A | 8.86 | N/A |
| Enterprise Value | $801.67M | $96.30B | Vertex |
| EV/Revenue Ratio | N/A | 8.43 | N/A |
| Gross Profit Margin (TTM) | N/A | 86.25% | N/A |
| Revenue per Share (TTM) | $0 | $44 | Vertex |
| Earnings per Share (Diluted) | $-0.42 | $14.05 | Vertex |
| Beta (Stock Volatility) | 0.72 | 0.44 | Vertex |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Trevi Therapeutics vs Vertex Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Trevi Therapeutics | -15.38% | 17.69% | 12.55% | 33.71% | 30.95% | 89.22% |
| Vertex | -0.71% | -0.40% | 1.74% | -14.24% | -20.36% | -2.77% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Trevi Therapeutics | 144.81% | 153.07% | 105.22% | -0.24% | -0.24% | -0.24% |
| Vertex | -18.72% | 36.18% | 48.66% | 217.76% | 988.36% | 1,933.66% |
News Based Sentiment: Trevi Therapeutics vs Vertex
Trevi Therapeutics
News based Sentiment: MIXED
Trevi Therapeutics experienced a month of both positive and negative developments. While Q2 earnings beat estimates and analysts maintain a 'Strong Buy' rating, insider selling and stock volatility create a mixed picture for investors. The company's progress with Haduvio and upcoming conference presentations will be key catalysts to watch.
Vertex
News based Sentiment: POSITIVE
September was a strong month for Vertex, marked by positive Q2 earnings, successful product launches, and continued pipeline development. While some analyst ratings are mixed, the overall narrative points to continued growth and diversification, making it a compelling investment story.
Performance & Financial Health Analysis: Trevi Therapeutics vs Vertex
| Metric | TRVI | VRTX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.00B | $101.15B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 3,475,230 | 1,277,750 |
| 90 Day Avg. Volume | 2,422,943 | 2,149,460 |
| Last Close | $8.25 | $394.53 |
| 52 Week Range | $2.36 - $9.92 | $362.50 - $519.88 |
| % from 52W High | -16.83% | -24.11% |
| All-Time High | $10.62 (Jun 03, 2019) | $519.88 (Nov 04, 2024) |
| % from All-Time High | -22.32% | -24.11% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.12% |
| Quarterly Earnings Growth | N/A | 0.12% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.32% |
| Operating Margin (TTM) | 0.00% | 0.39% |
| Return on Equity (TTM) | -0.36% | 0.23% |
| Debt to Equity (MRQ) | 0.45 | 8.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.63 | $67.02 |
| Cash per Share (MRQ) | $1.67 | $24.90 |
| Operating Cash Flow (TTM) | $-42,684,000 | $3.85B |
| Levered Free Cash Flow (TTM) | $-25,926,876 | $2.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Trevi Therapeutics vs Vertex
| Metric | TRVI | VRTX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -17.55 | 28.08 |
| Forward P/E | -17.19 | 21.02 |
| PEG Ratio | 0.70 | -0.22 |
| Price to Sales (TTM) | N/A | 8.86 |
| Price to Book (MRQ) | 5.06 | 5.89 |
| Market Capitalization | ||
| Market Capitalization | $1.00B | $101.15B |
| Enterprise Value | $801.67M | $96.30B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 8.43 |
| Enterprise to EBITDA | -15.61 | 20.06 |
| Risk & Other Metrics | ||
| Beta | 0.72 | 0.44 |
| Book Value per Share (MRQ) | $1.63 | $67.02 |
Financial Statements Comparison: Trevi Therapeutics vs Vertex
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TRVI | VRTX |
|---|---|---|
| Revenue/Sales | $0 | $2.96B |
| Cost of Goods Sold | N/A | $407.50M |
| Gross Profit | N/A | $2.56B |
| Research & Development | $7.81M | $978.40M |
| Operating Income (EBIT) | $-11.47M | $1.15B |
| EBITDA | $-10.31M | $1.34B |
| Pre-Tax Income | $-10.35M | $1.28B |
| Income Tax | $-11,000 | $250.10M |
| Net Income (Profit) | $-10.34M | $1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TRVI | VRTX |
|---|---|---|
| Cash & Equivalents | $19.37M | $4.67B |
| Total Current Assets | $105.62M | $10.01B |
| Total Current Liabilities | $6.87M | $3.78B |
| Long-Term Debt | $681,000 | $1.65B |
| Total Shareholders Equity | $99.46M | $16.50B |
| Retained Earnings | $-297.39M | $10.25B |
| Property, Plant & Equipment | $1.14M | $2.63B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TRVI | VRTX |
|---|---|---|
| Operating Cash Flow | $-10.98M | $404.90M |
| Capital Expenditures | N/A | $-40.70M |
| Free Cash Flow | $-13.48M | $778.20M |
| Debt Repayment | $-11,000 | $-1.30M |
| Common Stock Repurchase | N/A | $-696.60M |
Short Interest & Institutional Ownership Analysis
| Metric | TRVI | VRTX |
|---|---|---|
| Shares Short | 11.68M | 3.64M |
| Short Ratio | 6.36 | 1.54 |
| Short % of Float | 0.11% | 0.02% |
| Average Daily Volume (10 Day) | 3,475,230 | 1,277,750 |
| Average Daily Volume (90 Day) | 2,422,943 | 2,149,460 |
| Shares Outstanding | 93.60M | 256.94M |
| Float Shares | 90.63M | 255.58M |
| % Held by Insiders | 0.01% | 0.00% |
| % Held by Institutions | 0.93% | 0.98% |
Dividend Analysis & Yield Comparison: Trevi Therapeutics vs Vertex
| Metric | TRVI | VRTX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |